| antibody |
rat antimouse monoclonal |
septic mouse model |
prolonged survival |
(339) |
| |
humanized monoclonal |
pneumonic mouse model |
prolonged survival |
(340) |
| |
rabbit polyclonal |
rat liver injury
model |
decreased necrosis, inflammation, and fibrosis;
protected from
further liver injury |
(341) |
| |
goat
polyclonal |
Duchenne muscular dystrophy mouse model |
reduced necrosis and inflammation |
(342) |
| |
rabbit polyclonal |
systemic inflammation
mouse model |
reduced inflammation and activation of ERK1/2, p65, and IkB |
(343) |
| |
mouse monoclonal |
uremic mouse model |
reduces atherosclerosis |
(344) |
| |
antihuman/mouse monoclonal |
neuropathic pain mouse model |
attenuation of inflammation
and neuropathic pain |
(345) |
| |
antimouse/rat
monoclonal |
lung cancer mouse model |
suppressed
metastasis |
(346) |
| peptide |
S100P-derived RAGE antagonist |
glioma
and pancreatic cancer mouse model |
blocked ligands’
ability to bind and stimulate RAGE
and NFkB; reduced growth and metastasis of tumors |
(347) |
| |
inhibitory peptides for RAGE signaling |
SH-SY5Y and U-87MG cells |
reduced neuronal cell death, inhibit invasion
and migration
of glioma cells |
(348) |
| fusion protein |
TAT-SAM blocks interaction between
RAGE and SLP76, a critical adaptor protein for RAGE function |
septic mouse model |
decreases tissue damage and
RAGE cytokine release and downstream
signaling; prolonged survival of mice |
(349) |
| aptamer |
short DNA sequence created using SELEX |
mesangial cells and diabetic nephropathy rat model |
suppression of AGE-induced oxidative
stress, inflammation, fibrosis, albuminuria, and podocyte damage |
(350) |
| |
|
HCT116 cells and colorectal
cancer mouse model |
suppression of RAGE/NFkB signaling,
inhibition of tumor growth, decreases cell proliferation and migration |
(351) |
| |
|
melanoma mouse model |
inhibit tumor growth, decrease AGE and RAGE expression, lowered
oxidative stress and angiogenesis |
(352) |
| pharmacological inhibitor |
4,6-bis(4-chlorphenyl)pyrimidine analogue |
Alzheimer’s disease mouse model |
inhibition of amyloid-beta plaque
accumulation, improvement of cognitive function |
(353) |
| |
pyrazole-5-carboxamide |
Alzheimer’s disease mouse model |
inhibition of amyloid-beta plaque
accumulation |
(354) |
| |
FPS-ZM1 |
breast cancer mouse model |
impaired tumor growth and angiogenesis, decreased inflammation,
inhibition of metastasis |
(355) |
| |
|
Alzheimer’s disease mouse model |
decreased amyloid-beta plaque
accumulation in brain, suppressed inflammation, improved cognitive
performance |
(356) |
| |
|
acute lung injury mouse model |
decreased RAGE expression
and inflammation, restored cell contacts
and epithelium integrity |
(286) |
| |
azeliragon |
acute lung injury mouse model |
decreased RAGE
expression and inflammation, restored cell contacts
and epithelium integrity |
(286) |
| |
|
Alzheimer’s disease rat model |
reduced
AD injury, reversed neuronal damage, increased neurological
function |
(287) |
| |
semisynthetic glycosaminoglycan
ethers (SAGE) |
in vitro
models and rosacea mouse model |
inhibits ligands from
binding to RAGE, reduces inflammation |
(290) |
| |
|
secondhand smoke mouse model |
decreased inflammation, RAGE signaling; increased AXL and Gas6
protein expression |
(357,358) |
